

# Supplementary Materials: Utilization Trend and Comparison of Different Radiotherapy Modes for Patients with Early-Stage High–Intermediate-Risk Endometrial Cancer: A Real-World, Multi-Institutional Study

Kang Ren, Lijuan Zou, Tiejun Wang, Zi Liu, Jianli He, Xiaoge Sun, Wei Zhong, Fengju Zhao, Xiaomei Li, Sha Li, Hong Zhu, Zhanshu Ma, Shuai Sun, Wenhui Wang, Ke Hu, Xiaorong Hou, Lichun Wei and Fuquan Zhang

Table S1. Subgroup analyses in GOG249 HIR group

			Before matching				After matching			
			OS	DFS	DMFS	LRF S	OS	DFS	DMFS	LRFS
GOG-249	cN0	VB	85.40%	62.30%	71.50%	72.80%	72.80%	62.30%	71.50%	72.80%
		EBRT±VB	91.60%	87.40%	87.40%	92.10%	96.20%	93.00%	93.00%	96.20%
		P	0.236	<b>0.012</b>	<b>0.036</b>	<b>0.014</b>	0.194	<b>0.049</b>	0.084	<b>0.044</b>
	pN0	VB	95.70%	91.60%	93.40%	94.50%	95.70%	93.50%	93.40%	94.50%
		EBRT±VB	91.20%	87.40%	87.80%	92.00%	90.10%	81.60%	82.60%	89.40%
		P	0.626	0.548	0.329	0.92	0.617	0.192	0.108	0.869
Exclude FIGO II from GOG-249 cohort	cN0	VB	85.40%	62.30%	71.50%	72.80%	85.40%	62.30%	71.50%	72.80%
		EBRT±VB	89.50%	88.10%	88.10%	90.10%	86.10%	86.30%	86.20%	90.90%
		P	0.431	<b>0.025</b>	0.057	0.057	0.847	0.103	0.174	0.128
	pN0	VB	95.60%	93.40%	95.20%	94.40%	95.60%	93.40%	95.20%	94.30%
		EBRT±VB	90.90%	90.60%	90.50%	93.00%	89.50%	90.70%	90.60%	92.10%
		P	0.665	0.896	0.55	0.779	0.678	0.928	0.681	0.714

**Table S2.** Acute toxicities for patients treated with EBRT±VBT and V

	Whole patients(N=1038)			GOG-249 HIR(N=473)			PORTEC-2 HIR(N=184)			ESMO-ESGO-ESTRO HIR(N=207)		
	EBRT±VBT	VBT	P	EBRT±VBT T	VBT	P	EBRT±VBT	VBT	P	EBRT±VBT	VBT	P
<b>Hematological</b>												
0	317(55.1%)	435(94.0%)	<0.001	178 ( 54.8%)	136 ( 91.9%)	<0.001	61(68.5%)	89(93.7%)	<0.001	55 ( 57.3%)	94 ( 90.4%)	<0.001
1–2	231 (40.2%)	28(6.0%)		134 ( 41.2%)	12 ( 8.1%)		28(31.5%)	6(6.3%)		38 ( 39.6%)	10 ( 9.6%)	
3–4	27(4.7%)	0(0)		13 ( 4.0%)	0 ( 0.0%)					3 ( 3.1%)	0 ( 0)	
<b>Upper GI</b>												
0	334 (58.1%)	420(90.7%)	<0.001	190 <sub>a</sub> ( 58.5%)	130 ( 87.8%)	<0.001	190(58.5%)	130 <sub>(87.8%)</sub>	<0.001	53 ( 55.2%)	89 ( 85.6%)	<0.001
1–2	239(41.6%)	43(9.3%)		134 ( 41.2%)	18 ( 12.2%)		134(41.2%)	18(12.2%)		43(44.8%)	15(14.4%)	
3	2(0.3%)	0(0%)		1 ( 0.3%)	0 <sub>a</sub> ( 0.0%)		1(0.3%)	0(0)		0	0	
<b>Lower GI</b>												
0	185 <sub>a</sub> (32.2%)	377 (81.4%)	<0.001	115 ( 35.4%)	117 <sub>b</sub> ( 79.1%)	<0.001	34 ( 38.2%)	81 ( 85.3%)	<0.001	30 ( 31.3%)	75 ( 72.1%)	<0.001
1–2	386 (67.1%)	86 (18.6%)		206 ( 63.4%)	31 ( 20.9%)		54 ( 60.7%)	14 ( 14.7%)		66 ( 68.8%)	29 ( 27.9%)	
3	4 ( 0.7%)	0 <sub>a</sub> ( 0.0%)		4 ( 1.2%)	0 ( 0.0%)		1 ( 1.1%)	0 ( 0%)				
<b>Urinary Tract</b>												
0	464 (51.4%)	438 (48.6%)	<0.001	274 <sub>a</sub> ( 84.3%)	137 ( 92.6%)	0.044	70 <sub>a</sub> ( 78.7%)	90 ( 94.7%)	0.0047	75 ( 78.1%)	100 ( 96.2%)	<0.001
1–2	110 (81.5%)	25 (18.5%)		50 ( 15.4%)	11 ( 7.4%)		17 ( 19.1%)	4 ( 4.2%)		21 ( 21.8%)	4 ( 3.8%)	
3	1 (100.0%)	0 (0.0%)		1 ( 0.3%)	0 ( 0.0%)		2 ( 2.2%)	1 ( 1.1%)				

Note: GI gastrointestinal, EBRT External Beam Radiation, VBT Vaginal Brachytherapy.